Advertisement

Use of Antibiotics in Pregnant Patients in the ICU

  • Josep-E. Baños
  • Magí Farré

Abstract

The critically sick pregnant patient challenges the intensive care physician. Several features, such physiological changes associated with pregnancy, specific obstetric diseases and the presence of the fetus greatly complicate the assessment and treatment of these patients [1]. Several studies have analyzed obstetric admissions to the intensive care unit ICU [1–10]. They conclude that less than 1% of deliveries is referred to the ICU, mainly by preeclampsia, and maternal mortality may be highly variable (from 0 in the study of Lapinsky et al. [1] to 20% in Collop and Sahn’s study [6]). Bacterial infections were a significant, although not highly prevalent, cause of sickness in these critically ill patients.

Keywords

Pregnant Woman Obstet Gynecol Amniotic Fluid Antimicrob Agent Pregnant Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lapinsky SE, Kruczynski K, Seaward GR, Farine D, Grossman RF. Critical care management of the obstetric patient. Can J Anaesth 44:325, 1997.PubMedCrossRefGoogle Scholar
  2. 2.
    Graham SG, Luxton MC. The requirement for intensive care support for the pregnant population. Anaesthesia 44:581, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    Kirshon B, Hinkley CM, Cotton DB, Miller J. Maternal mortality in a maternal-fetal medicine intensive care unit. J Reprod Med 35:25, 1990.PubMedGoogle Scholar
  4. 4.
    Mabie WC, Sibai BM. Treatment in an obstetric intensive care unit. Am J Obstet Gynecol 162:1, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Kilpatrick SJ, Matthay MA. Obstetric patients requiring critical care. A five-year review. Chest 101:1407, 1992.PubMedCrossRefGoogle Scholar
  6. 6.
    Collop NA, Sahn SA. Critical illness in pregnancy. An analysis of 20 patients admitted to a medical intensive care unit. Chest 103:1548, 1993.PubMedCrossRefGoogle Scholar
  7. 7.
    Monaco TJ Jr, Spielman FJ, Katz VL. Pregnant patients in the intensive care unit: a descriptive analysis. South Med J 86:414, 1993.PubMedCrossRefGoogle Scholar
  8. 8.
    Lewinsohn G, Herman A, Leonov Y, Klinowski E. Critically ill obstetrical patients: outcome and predictability. Crit Care Med 22:1412, 1994.PubMedCrossRefGoogle Scholar
  9. 9.
    Bouvier-Colle MH, Salanave B, Ancel PY, Varnoux N, Fernández H, Papiernik E, Breart G, Benhamou D, Boutroy P, Caillier I, Dumoulin M, Fournet P, Elhassani M, Puech F, Poutot C. Obstetric patients treated in intensive care units and maternal mortality. Regional teams for the survey. Eur J Obstet Gynecol Reprod Biol 65:121, 1996.PubMedCrossRefGoogle Scholar
  10. 10.
    El-Solh AA, Grant BJB. A comparison of severity of illness scoring systems for critically ill obstetrical patients. Am J Resp Crit Care Med 153:A362, 1996.CrossRefGoogle Scholar
  11. 11.
    Wise R. Antibiotics. In Rubin P (ed). Prescribing in pregnancy. 2nd edn, London: BMJ Pub Group, 1995:29.Google Scholar
  12. 12.
    Gilstrap LC, Little BB. Antimicrobial agents during pregnancy. In Gilstrap LC, Little BB (eds). Drugs and pregnancy 2nd edn, New York: Chapman and Hall, 1999:45.Google Scholar
  13. 13.
    Lee W, Clark SL, Cotton DB, Gonik B, Phelan J, Faro S, Giebel R. Septic shock during pregnancy. Am J Obstet Gynecol 159:410, 1988.PubMedGoogle Scholar
  14. 14.
    Gallagher MW, Repke JT, Goldstein PJ. Pharmacologic approach to the critically ill obstetric patient. In Chernow B (ed). The pharmacologic approach to the critically ill patient. Baltimore: William and Wilkins, 1994:847.Google Scholar
  15. 15.
    Mabie WC, Barton JR, Sibai B. Septic shock in pregnancy. Obstet Gynecol 90:553, 1997.PubMedCrossRefGoogle Scholar
  16. 16.
    Hamod KA, Khouzami VA. Antibiotics in pregnancy. In Nyebil JR (ed). Drug use in pregnancy. 2nd edn, Philadelphia: Lea and Fabiger, 1988:29.Google Scholar
  17. 17.
    Theis JGW, Koren G. Maternal and fetal clinical pharmacology. In En Speight TM, Holford HG (eds). Avery’s drug treatment. 4th edn, Auckland: Adis, 1997:75.Google Scholar
  18. 18.
    Folb PI, Dukes MNG. Drug safety in pregnancy. Amsterdam: Elsevier, 1993.Google Scholar
  19. 19.
    Ho JL, Barza M. Chemotherapy of infection. In Gleicher N (ed). Principles of medical therapy in pregnancy. New York: Plenum Med. Book Co., 1985:406.CrossRefGoogle Scholar
  20. 20.
    Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 28:235, 1995.PubMedCrossRefGoogle Scholar
  21. 21.
    Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328, 1997.PubMedCrossRefGoogle Scholar
  22. 22.
    Rubin PC. Prescribing in pregnancy. General principles. BMJ 293:1415, 1986.PubMedCrossRefGoogle Scholar
  23. 23.
    Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 5th edn. Baltimore: William and Wilkins, 1998.Google Scholar
  24. 24.
    Kullander K, Kallen B. A prospective study of drugs and pregnancy. Acta Obstet Gynecol Scand 55:287, 1976.PubMedCrossRefGoogle Scholar
  25. 25.
    Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton: Publishing Sciences Group, 1977.Google Scholar
  26. 26.
    Kunin CM. Clinical pharmacology of the new penicillins. I. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin Pharmacol Ther 7:166, 1966.Google Scholar
  27. 27.
    MacAulay MA, Berg SA, Charles D. Placental transfer of dicloxacillin at term. Am J Obstet Gynecol 102:1162, 1968.PubMedGoogle Scholar
  28. 28.
    Philipson A. Pharmacokinetics of ampicillins during pregnancy. J Infect Dis 136:370, 1975.CrossRefGoogle Scholar
  29. 29.
    Philipson A. Pharmacokinetics of antibiotics in pregnancy and labour. Clin Pharmacokinet 4:297, 1979.PubMedCrossRefGoogle Scholar
  30. 30.
    Wasz-Hockert O, Nummi S, Vuopala S, Jarvinen P. Transplacental passage of azidocillin, ampicillin and penicillin G during early and late pregnancy. Acta Paediatr Scand (Suppl) 206:109, 1970.CrossRefGoogle Scholar
  31. 31.
    Woltz J, Zintel H. The transmission of penicillin to amniotic fluid and fetal blood in the human. Am J Obstet Gynecol 49:663, 1945.Google Scholar
  32. 32.
    Nathan L, Bawdon RE, Sidawi JE, Stettler RW, Mclntire DM, Wendel GD Jr. Penicillin levels following the administration of benzathine penicillin G in pregnancy. Obstet Gynecol 82:338, 1993.PubMedGoogle Scholar
  33. 33.
    Heikkilä AM, Erkkola RV. The need for adjustment of dosage regimen of penicillin V during pregnancy. Obstet Gynecol 81:919, 1993.PubMedGoogle Scholar
  34. 34.
    Ravid R, Toaff R. On the possible teratogenicity of antibiotic drugs administered during pregnancy — a prospective study. In Klinberg M, Abramovici A, Chemki J (eds). Drugs and fetal development. New York: Plenum, 1972:105.Google Scholar
  35. 35.
    Noschel VH, Peiker G, Schroder S, Meinhold P, Muller B. Untersuchungren zur pharmakokinetik von antibiotika und sulfanilamiden in der schwangerschaft und unter der geburt. Zentralbl Gynakol 104:1514, 1982.PubMedGoogle Scholar
  36. 36.
    Kraybill EN, Chaney NE, McCarthy LR. Transplacental ampicillin: inhibitory concentrations in neonatal serum. Am J Obstet Gynecol 138:793, 1980.PubMedGoogle Scholar
  37. 37.
    Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am J Obstet Gynecol 168:667, 1993.PubMedCrossRefGoogle Scholar
  38. 38.
    MacAulay MA, Abou-Sabe M, Charles D. Placental transfer of ampicillin. Am J Obstet Gynecol 96:943, 1966.PubMedGoogle Scholar
  39. 39.
    Morales WJ, Angel JL, O’Brien WF, Knuppel RA. Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstet Gynecol 173:721, 1989.Google Scholar
  40. 40.
    Zierler S. Maternal drugs and congenital heart disease. Obstet Gynecol 65:155, 1985.PubMedGoogle Scholar
  41. 41.
    Jakobi P, Neiger R, Merzbach D, Paldi E. Single-dose antimicrobial therapy in the treatment of asymptomatic bacteriuria in pregnancy. Am J Obstet Gynecol 156:1148, 1987.PubMedGoogle Scholar
  42. 42.
    Bergogne-Berenzin E, Lambert-Zechovsky N, Rouvillois JL. Etude du passage transplacentaire des beta-lactamines. J Gynecol Obstet Biol Reprod (Paris) 8:359–364, 1979.Google Scholar
  43. 43.
    Matsuda S. Augmentin treatment in obstetrics and gynaecology. In Leigh DA, Robinson OPW (eds). Augmentin: Proceedings of an international symposium. Montreux, Switzerland. July 1981. Excerpta Medica 1982:179.Google Scholar
  44. 44.
    Takase Z, Shirafuji H, Uchida M. Clinical and laboratory studies on BRL25000 (clavulanic acid-amoxicillin) in the field of obstetrics and gynecology. Chemotherapy (Tokyo) 30 (Suppl 2):538, 1982.Google Scholar
  45. 45.
    Pedler SJ, Bint AJ. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother 27:508, 1985.PubMedCrossRefGoogle Scholar
  46. 46.
    Prigot A, Froix C, Rubin E. Absorption, diffusion, and excretion of new penicillin, oxacillin. Antimicrob Agents Chemother 2:402, 1962.Google Scholar
  47. 47.
    Depp R, Kind A, Kirby W, Johnson W. Transplacental passage of methicillin and dicloxacillin into the fetus and amniotic fluid. Am J Obstet Gynecol 107:1054, 1970.PubMedGoogle Scholar
  48. 48.
    MacAulay M, Molloy W, Charles D. Placental transfer of methicillin. Am J Obstet Gynecol 115:58, 1973.PubMedGoogle Scholar
  49. 49.
    Biro L, Ivan E, Elek E, Arr M. Data on the tissue concentration of antibiotics in man. Tissue concentrations of semi-synthetic penicillins in the fetus. Int Z Pharmakol Ther Toxikol 4:321, 1970.Google Scholar
  50. 50.
    Elek E, Ivan E, Arr M. Passage of penicillins from mother to fetus in umans. Int J Clin Pharmacol Ther Toxicol 6:223, 1972.Google Scholar
  51. 51.
    Cho N, Nakayama T, Vehara K, Kunii K. Laboratory and clinical evaluation of ticarcillin in the field of obstetrics and gynecology. Chemotherapy (Tokyo) 25:2911, 1977.Google Scholar
  52. 52.
    Lockwood CJ, Costigan K, Ghidini A, Wein R, Cetrulo C, Alvarez M, Berkowitz L. Double-blind, placebo-controlled trial of piperacillin sodium in preterm membrane rupture. Am J Obstet Gynecol 169:970, 1993.PubMedCrossRefGoogle Scholar
  53. 53.
    Brown CEL, Christmas JT, Bawdon RE. Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. Am J Obstet Gynecol 163:938, 1990.PubMedCrossRefGoogle Scholar
  54. 54.
    Heikkilä A, Erkola R. Pharmacokinetics of piperacillin during pregnancy. J Antimicrob Chemother 28:419, 1991.PubMedCrossRefGoogle Scholar
  55. 55.
    Bourget P, Sertin A, Lesne-Hulin A, Fernandez H, Ville Y, Van Peborgh P. Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam. Eur J Obstet Gynecol Reprod Biol 76:21, 1998.PubMedCrossRefGoogle Scholar
  56. 56.
    Brown CEL, Christmas JT, Bawdon RE. Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. Am J Obstet Gynecol 162: 549–554, 1990.CrossRefGoogle Scholar
  57. 57.
    Voigt R, Schroder S, Peiker G. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. Chemotherapy 31:417–424, 1995.CrossRefGoogle Scholar
  58. 58.
    Chow AW, Jewesson PJ. Pharmacokinetics and safety of antimicrobials agents during pregnancy. Rev Infect Dis 7:287, 1985.PubMedCrossRefGoogle Scholar
  59. 59.
    Graham JE, Oshiro BT, Blanco JD. Limited spectrum (first generation) cephalosporins. Obstet Gynecol Clin North Amer 19:449, 1992.Google Scholar
  60. 60.
    Eriksen NL, Blanco JD. Extended-spectrum (second- and third-generation) cephalosporins. Obstet Gynecol Clin North Amer 19:461, 1992.Google Scholar
  61. 61.
    Martens MG. Cephalosporins. Obstet Gynecol Clin North Amer 16:291, 1989.Google Scholar
  62. 62.
    Heikkila A, Renkonen O-V, Erkkola R. Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob Agents Chemother 36:2652, 1992.PubMedCrossRefGoogle Scholar
  63. 63.
    Hirabayashi K, Okada E. Pharmacokinetic and clinical studies of imipenem/cilstatin sodium in the perinatal period. Jpn J Antibiot 11:1797, 1988.Google Scholar
  64. 64.
    Graham JM, Blanco JD, Oshiro BT, Magee KP. Gentamicin levels in pregnant women with pyelonephritis. Am J Perinatol 11:40, 1994.PubMedCrossRefGoogle Scholar
  65. 65.
    Fernández H, Bourget P, Deluis C. Fetal levels of tobramycin following maternal administration. Obstet Gynecol 76:992, 1990.PubMedGoogle Scholar
  66. 66.
    Bourget P, Fernandez H, Delouis C, Ribou F. Transplacental passage of vancomycin during the second trimester of pregnancy. Obstet Gynecol 78:908, 1991.PubMedGoogle Scholar
  67. 67.
    Reyes MP, Ostrea EM, Cabinian AE, Schamit C, Rintelmann W. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol 161:977, 1989.PubMedCrossRefGoogle Scholar
  68. 68.
    Philipson A, Sabaath LD, Charles D. Erythromycin absorption and elimination in pregnant women. Clin Pharmacol Ther 19:68, 1976.PubMedGoogle Scholar
  69. 69.
    McDormack WM, George H, Donner A, Kodgis LF, Albert S, Lowe EW, Kass EH. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother 12:630, 1977.CrossRefGoogle Scholar
  70. 70.
    Garland SM, O’Reilly MA. The risks and benefits of antimicrobial therapy in pregnancy. Drug Saf 13:188, 1995.PubMedCrossRefGoogle Scholar
  71. 71.
    Ben David S, Einarson T, Ben David Y, Nulman I, Pastuszak A, Koren G. The safety of nitrofurantoin during the first trimester of pregnancy: meta-analysis. Fundamen Clin Pharmacol 9:503, 1995.CrossRefGoogle Scholar
  72. 72.
    Philipson A, Sabaath LD, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med 288:1219, 1973.PubMedCrossRefGoogle Scholar
  73. 73.
    Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first trimester vaginitis drug therapy. Obstet Gynecol 82:348, 1993.Google Scholar
  74. 74.
    Piper JM, Mitchelm EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 82:348, 1993.PubMedGoogle Scholar
  75. 75.
    Schaefer C, Amoura-Elefant E, Vial T, Omory A, Garbis H, Robert E, Rodriguez-Pinilla E, Pexiedir T, Prapas N, Merlob P. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Gynecol Reprod Biol 69:83, 1996.CrossRefGoogle Scholar
  76. 76.
    Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, Schick B, Bonati M, Moretti M, Lalkin A, Pastuszak A, Koren G. Pregnancy outcome following gestational exposure to fluoroquinolone: a multicenter prospective controlled study. Antimicrob Agents Chemother 42:1336, 1998.PubMedGoogle Scholar
  77. 77.
    Giamarellou H, Kolohythas E, Petrikkos G, Gazis J, Aravantinos D, Sfikakis P. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 87 (Suppl 5A):49S, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Josep-E. Baños
  • Magí Farré

There are no affiliations available

Personalised recommendations